NYSE · ZBH
Healthcare · Medical - Devices
$92.08
Down-$0.47 (-0.50%)
Updated Oct 14, 2026, 7:58 PM
SID Score
5.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance · ZBH
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 13, 2026
ZBH closed at $92.08 after 21 trading sessions, down 6.43% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 13, 2026 | $92.87 | $93.85 | $91.39 | $92.08 | 2.3M |
| Oct 12, 2026 | $89.28 | $92.23 | $89.18 | $92.17 | 1.8M |
| Oct 9, 2026 | $88.93 | $90.21 | $88.40 | $89.14 | 1.6M |
| Oct 8, 2026 | $88.36 | $89.07 | $87.31 | $88.88 | 2.51M |
| Oct 7, 2026 | $89.11 | $90.0087 | $88.32 | $88.49 | 1.99M |
| Oct 6, 2026 | $91.41 | $91.95 | $89.55 | $89.68 | 1.68M |
| Oct 5, 2026 | $89.02 | $92.025 | $88.2252 | $91.57 | 2.29M |
| Oct 2, 2026 | $88.13 | $88.805 | $87.11 | $88.29 | 1.99M |
| Oct 1, 2026 | $88.68 | $89.295 | $87.54 | $88.06 | 2.3M |
| Sep 30, 2026 | $90.82 | $90.865 | $88.82 | $88.83 | 2.58M |
| Sep 29, 2026 | $90.96 | $91.59 | $90.60 | $91.34 | 1.46M |
| Sep 28, 2026 | $90.76 | $91.84 | $90.09 | $91.62 | 1.63M |
| Sep 25, 2026 | $89.43 | $91.84 | $89.24 | $91.04 | 1.79M |
| Sep 24, 2026 | $91.43 | $92.505 | $89.02 | $89.69 | 2.65M |
| Sep 23, 2026 | $92.60 | $93.25 | $89.87 | $90.88 | 2.97M |
| Sep 22, 2026 | $95.43 | $95.47 | $93.36 | $93.98 | 1.71M |
| Sep 21, 2026 | $95.32 | $95.66 | $93.64 | $94.32 | 1.6M |
| Sep 18, 2026 | $94.04 | $96.165 | $93.715 | $95.36 | 3.95M |
| Sep 17, 2026 | $96.70 | $97.19 | $94.20 | $94.25 | 2.2M |
| Sep 16, 2026 | $97.75 | $98.41 | $96.39 | $96.78 | 1.89M |
| Sep 15, 2026 | $96.44 | $99.1825 | $95.87 | $98.41 | 3.62M |
The latest Smart Investors Daily articles mentioning ZBH.
Company
Market Activity
Research & News
ZBH research
Company profile and research snapshot.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Equal-Weight | — |
| Aug 10, 2026 | Canaccord Genuity | Hold | — |
| Aug 7, 2026 | Truist Securities | Hold | — |
| Aug 6, 2026 | Bernstein | Market Perform | — |
| Aug 6, 2026 | Stifel | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 7, 2026
Barclays analyst Christopher Pasquale initiates coverage on Zimmer Biomet Holdings (NYSE:ZBH) with a Equal-Weight rating and announces Price Target of $100.
Yahoo · Oct 6, 2026
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its third quarter earnings conference call will be webcast on Wednesday, November 4, 2026, at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET.
Yahoo · Oct 2, 2026
Intuitive Surgical (ISRG) grows faster and earns a higher operating margin than any of the five rivals in its health care peer group. It is also the most expensive of the six when price is measured against earnings. It holds that place even after its stock fell 10.3% over the past twelve months. How much more do you pay for a dollar of Intuitive's earnings than for a dollar of a rival's.
Yahoo · Sep 28, 2026
Stryker's sales have grown about 10% a year on average over the past three years, and so have ResMed's. That shared growth rate in medical devices is the bet the two have in common. Stryker (SYK) is the giant, selling hospitals everything from hip and knee products to capital equipment. ResMed is a sleep device maker with less than a quarter of Stryker's revenue. Stryker costs 32.6 times its past year's earnings, against 21.9 times for ResMed. So does Stryker's reach justify that higher price? T
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ZBH.
